Reply to alffenaar et al

Clinical Infectious Diseases

Volumn 64, Issue 1, 2017, Pages 105-106

  Peloquin, Charles A ^a   Dorman, Susan E ^b   Vernon, Andrew ^c   Migliori, Giovanni Battista ^d   Nahid, Payam ^e  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; ETHIONAMIDE; ISONIAZID; RIFAPENTINE; TUBERCULOSTATIC AGENT;

CONCENTRATION RESPONSE; COST CONTROL; DRUG EXPOSURE; DRUG MONITORING; HUMAN; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL; COMMUNICABLE DISEASE; DISEASE PREDISPOSITION; PUBLIC HEALTH SERVICE; UNITED STATES;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COMMUNICABLE DISEASES; DISEASE SUSCEPTIBILITY; HUMANS; TUBERCULOSIS; UNITED STATES;

EID: 85015182993     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw679     Document Type: Letter

References (10)

1. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63:e147-95.
2. Sotgiu G, Nahid P, Loddenkemper R, Abubakar I, Miravitlles M, Migliori GB. The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. Eur Respir J 2017; 48:963-71.
3. Alffenaar JC, Tiberi S, Verbeeck RK, Heysell SK, Grobusch MP. Therapeutic drug monitoring in tuberculosis: practical application for physicians. Clin Infect Dis 2017; 64:104-5.
4. Pasipanodya JG, Nuermberger E, Romero K, Hanna D, Gumbo T. Systematic analysis of hollow fiber model of tuberculosis experiments. Clin Infect Dis 2015; 61(suppl 1):S10-7.
5. Rosenthal IM, Tasneen R, Peloquin CA, et al. Doseranging comparison of rifampin and rifapentine in two pathologically distinctmurinemodels of tuberculosis. Antimicrob Agents Chemother 2012; 56:4331-40.
6. Dorman SE, Savic RM, Goldberg S, et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med 2015; 191:333-43.
7. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: An update. Drugs 2014; 74:839-54.
8. Egelund EF, Alsultan A, Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clin Pharmacol Ther 2015; 98:387-93.
9. Boeree MJ, Diacon AH, Dawson R, et al. A doseranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015; 191:1058-65.
10. Zuur MA, Bolhuis MS, Anthony R, et al. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opin Drug Metab Toxicol 2016; 12:509-21.